Streetbeat News

ICCM

IceCure Medical Ltd

https://www.icecure-medical.com

Industry

Medical - Devices

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

IceCure Medical Ltd. (NASDAQ:ICCM) has received FDA clearance for its next-generation XSense Cryoablation System with CryoProbes, a minimally-invasive technology for tumor destruction.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:33 pm

Shares of Nurix Therapeutics (NRIX) surged 12.1% in pre-market trading following positive clinical trial results. Other notable pre-market movers include Scinai Immunotherapeutics (SCNI), Interactive Strength (TRNR), ENDRA Life Sciences (NDRA), and The Aaron’s Company (AAN), which saw significant gains. Conversely, Ovid Therapeutics (OVID) and Kaival Brands Innovations (KAVL) experienced substantial declines.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 12:43 pm

IceCure Medical Ltd. (NASDAQ:ICCM) presented interim data from its ICESECRET kidney cancer trial at the 3rd Annual Israeli Conference on Interventional Radiology. The data showed that the ProSense® System is safe and effective, with an 89.5% recurrence-free rate. More data is expected in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 12:32 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:34 am

IceCure Medical has announced that the FDA will hold an advisory panel meeting to review its ProSense System for tumor cryoablation. This review is a significant step towards potential approval and commercialization in the U.S. market.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:35 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 10:21 am

Icecure Medical (NASDAQ:ICCM) reported Q1 EPS of $(0.08), meeting analyst expectations, but missed sales estimates with $743K, a 4.65% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:45 pm

IceCure Medical (ICCM) is anticipated to receive a total of $13.2M from Terumo during the initial term, including $4M already received, $8.2M upon order completion, and $1M for milestone-based payments.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:45 pm

An independent study in Japan showed 0% breast cancer local recurrence 5 years after treatment with IceCure's ProSense, demonstrating its potential as a standard treatment for early-stage breast cancer. The study, published in Breast Cancer journal, highlighted excellent cosmetic outcomes, high patient satisfaction, and improved quality of life post-cryoablation. IceCure's distribution partner in Japan, Terumo Corporation, plans to submit a regulatory clearance application for ProSense in H2 2024. IceCure expects to receive a total of $13.2 million from Terumo for exclusive distribution rights in Japan.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:45 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 3:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.